Septodont is a pharmaceutical and medical device company and was founded in 1932 by Annie & Nestor Schiller. Dedicated to serving the needs of dental professionals wherever they are, the company extended its global presence in the world by opening foreign subsidiaries in India (1998), China (2001), Brazil (2003) and in European countries (United Kingdom, Germany, Poland, Benelux, Italy and Spain). Septodont also acquired 2 companies in Brazil (TDV in 2014 and DLA in 2016) and one in Canada (Duoject – 2015, an engineering design firm for injection devices). In 2016 a new state-of-the-art manufacturing unit for injectable anesthetics has been opened in Saint-Maur-des-Fossés (France). With 500 million cartridges of local anesthetic produced every year, Septodont is today world leader of dental anesthesia. The group counts 1,700 employees and remains a 100% family owned company under the leadership of its CEO, Olivier Schiller.
Since its foundation in 1932, Septodont has been at the forefront of pharmaceutical dentistry-developing, manufacturing and distributing a wide range of high quality dental products globally. For Pain Management, the company offers topical anesthetics, local anesthetics, safety devices, needles and syringes, and other innovative products for endodontics and restorative, regeneration and surgery. Beyond dental anesthesia, Septodont also invested in R&D towards bioactive and biocompatible therapeutic solutions, which led to the introduction of Biodentine and Bioroot RCS, two products based on the ABS Technology (Active Biosilicate Technology). Looking forward, Septodont is leveraging its competencies to bring more solutions in the medical field.